Aurinia Pharmaceuticals and Teva Settle Patent Dispute Over LUPKYNIS
On August 19, Aurinia Pharmaceuticals (NASDAQ:AUPH) reached a patent settlement with Teva Pharmaceuticals Industries Limited (NYSE:TEVA), resolving their U.S. dispute over the lupus nephritis drug LUPKYNIS. Teva acknowledged that its proposed generic version of voclosporin infringes on Aurinia's patents and agreed to delay commercialization until December 7, 2036—effectively removing Teva as a near-term competitor. This settlement removes the risk of generic entry for over ten years but does not resolve ongoing litigation with other companies like Dr. Reddy’s and Sandoz. Aurinia continues to perform well financially, reporting strong Q2 revenue growth and robust free cash flow generation in 2026. Meanwhile, Teva faces headwinds from declining generic sales but is seeing momentum in its branded drug portfolio.
Topics: Aurinia Pharmaceuticals generic drugs intellectual property LUPKYNIS Teva Pharmaceuticals